恩替卡韦治疗乙型肝炎肝硬化患者疗效及其对血清甲状腺素水平影响初步研究

doi:10.3969/j.issn.1672-5069.2017.05.033

Abstract

Huang Jinlong.. Application of entecavir in treatment of patients with hepatitis B-induced liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 618-619.

[1] 茅益民，尤红，贾继东. 乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 国际消化病杂志，2014，34（2）: 138-148.
[2] Walayat S，Ahmed Z，Martin D，et al. Recent advances in vaccination of non-responders to standard dose hepatitis b virus vaccine. World J Hepatol，2015，7（24）:2503-2539.
[3] 刘碧霞，张伦理，李小鹏，等. 慢性乙型肝炎不规范停用恩替卡韦复发后再次恩替卡韦治疗的效果. 广东医学，2015，36（8）:1263-1265.
[4] 张静. 恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效分析. 中国现代药物应用，2014，8（24）:71-72.
[5] Li PL，Tan HN，Xu DQ，et al. Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant. Carbohydrate Polymers，2014，110:446-455.
[6] 段树鹏，朱利红. 不同核苷类抗病毒药物用于乙型肝炎肝硬化的对比分析.中国继续医学教育，2015，10（12）:163-164.
[7] Zoutendijk R，Reijnders JG，Zoulim F，et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis b patients with cirrhosis. Gut，2013，62（5）:760-765.
[8] 王爱瑶，方静. 恩替卡韦对乙型肝炎肝硬化患者肝脏组织学的影响评价. 现代诊断与治疗，2014，25（22）:5114-5115.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[10] Rauscher I，Eiber M，Ganter C，et al. Evaluation of t1ρ as a potential MR biomarker for liver cirrhosis:Comparison of hegpthy control subjects and patients with liver cirrhosis. Eur J Radiol，2014，83（6）:900-904.
[11] 李磊，刘伟，陈玉涵，等. 不同核苷酸类似物抗病毒治疗方案治疗失代偿期乙型肝炎肝硬化的临床研究. 北京医学，2014，36（12）:1017-1021.
[12] Arase Y，Kobayashi M，Suzuki F，et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology，2013，57（3）:964-973.
[13] 王驭风，夏澍，钱卫，等. 核苷类抗病毒药物治疗乙型肝炎肝硬化患者的疗效分析. 实用临床医药杂志，2013，17（14）:43-45.
[14] 朱刚剑，苏传真，王健，等. 恩替卡韦治疗代偿期乙型肝炎肝硬化患者过程中血清甲状腺激素的变化. 实用医学杂志，2013，29 （3）:461-463.
[15] Shouval D，Lai CL，Chang TT，et al. Relapse of hepatitis b in HBeAg-negative chronic hepatitis b patients who discontinued successful entecavir treatment:the case for continuous antiviral therapy. J Hepatol，2009，50（2）:289-295.
[16] Wu K，Ding J，Chen C，et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology，2012，56（6）:2255-2267.
[17] Mangerich A，Knutson CG，Parry NM，et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci USA，2012，109（27）:E1820-E18209.

Application of entecavir in treatment of patients with hepatitis B-induced liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[13]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[14]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[15]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.